Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
Top Cited Papers
Open Access
- 1 September 2013
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 15 (9), 1062-1073
- https://doi.org/10.1093/eurjhf/hft052
Abstract
Aims Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone system (RAAS), potentially beneficial counter‐regulatory systems are also active in HF. These promote vasodilatation and natriuresis, inhibit abnormal growth, suppress the RAAS and sympathetic nervous system, and augment parasympathetic activity. The best understood of these mediators are the natriuretic peptides which are metabolized by the enzyme neprilysin. LCZ696 belongs to a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNIs), which both block the RAAS and augment natriuretic peptides. Methods Patients with chronic HF, NYHA class II–IV symptoms, an elevated plasma BNP or NT‐proBNP level, and an LVEF of ≤40% were enrolled in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortailty and morbidity in Heart Failure trial (PARADIGM‐HF). Patients entered a single‐blind enalapril run‐in period (titrated to 10 mg b.i.d.), followed by an LCZ696 run‐in period (100 mg titrated to 200 mg b.i.d.). A total of 8436 patients tolerating both periods were randomized 1:1 to either enalapril 10 mg b.i.d. or LCZ696 200 mg b.i.d. The primary outcome is the composite of cardiovascular death or HF hospitalization, although the trial is powered to detect a 15% relative risk reduction in cardiovascular death. Perspectives PARADIGM‐HF will determine the place of the ARNI LCZ696 as an alternative to enalapril in patients with systolic HF. PARADIGM‐HF may change our approach to neurohormonal modulation in HF. Trial registration NCT01035255This publication has 46 references indexed in Scilit:
- Mendelian Randomization Study of B-Type Natriuretic Peptide and Type 2 Diabetes: Evidence of Causal Association from Population StudiesPLoS Medicine, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyThe Lancet, 2010
- Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptideEuropean Journal of Heart Failure, 2009
- Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedemaBritish Journal of Pharmacology, 2008
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureThe New England Journal of Medicine, 2001
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureThe New England Journal of Medicine, 1987
- A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in ratsLife Sciences, 1981